DTM vs REGN · P/E 28, rev $981.0M vs P/E 14, rev $14.34B
DT Midstream Inc (DTM) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
DT Midstream Inc (DTM) is a oil & gas midstream company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported DTM revenue for 2024-12-31 was $981.0M. Net income was $367.0M. Revenue was up 6.4% from 2023-12-31 to 2024-12-31. DTM currently screens at market cap $10.44B and trailing P/E 28.0.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
DTM currently screens at market cap $10.44B and trailing P/E 28.0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the DTM and REGN stock pages for the full models.
Not investment advice.